| The Regents of the University of California Office of Technology Transfer Patent applications |
| Patent application number | Title | Published |
|---|
| 20120302461 | GFP MUTAGENESIS AMPLIFICATION: USE OF A FLUORESCENCE-ANTIBIOTIC RESISTANCE FUSION DUAL REPORTER CONSTRUCT TO PROVIDE QUANTITATIVE AND HIGHLY SENSITIVE DETECTION OF MUTATIONS - A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-β-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence. This dual reporter is placed in a multicopy plasmid to increase the number of targets, with a reversion site at the N-terminus. Rare mutations at the reversion site allow read-through of the fusion protein, producing both beta-lactamase (providing antibiotic resistance) and GFP (emitting fluorescence). In the presence of carbenicillin, beta-lactamase production confers a selective advantage that allows amplification of mutant plasmids, raising the level of fluorescence emitted by GFP to levels that are detectable by fluorimetry. A window of time can be found where fluorescence is proportional to the number of mutation events at the reversion site, making fluorescence a quantitative measure of mutagenesis. Quantitative (as opposed to binary) detection of mutations allows substantial savings in test sample. This has applications in drug discovery, allowing high-throughput screening for DNA-targeting compounds and early pre-screening of leads for potential carcinogenic activity. The increased sensitivity of this assay also facilitates monitoring complex environmental samples. | 11-29-2012 |
| 20120108502 | NOVEL ANTI-PARASITIC COMPOUNDS - A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease. | 05-03-2012 |
| 20120095180 | ISOLATION OF A C5-DEPROTONATED IMIDAZOLIUM, A CRYSTALLINE ABNORMAL N-HETEROCYCLIC CARBENE - The present invention provides metal-free abnormal N-heterocyclic carbenes, also known as imidazol-5-ylidenes and metal complexes of abnormal N-heterocyclic carbenes. The present invention also provides methods of making metal-free abnormal N-heterocyclic carbenes and metal complexes of abnormal N-heterocyclic carbenes. The present invention also provides methods of using metal-free abnormal N-heterocyclic carbenes and metal complexes of abnormal N-heterocyclic carbenes in catalytic reactions. | 04-19-2012 |
| 20110288023 | CANCER DRUG DELIVERY USING MODIFIED TRANSFERRIN - The invention provides modified Transferrin (Tf) molecules and conjugates of the Tf molecules with a therapeutic agent. The invention also provides methods of treating cancer wherein the therapeutic agents are chemotherapeutic agents. The modified Tf molecules improve the delivery of the conjugated agent to a target tissue. In some embodiments, the modified Tf molecule has a mutation which decreases the release of bound iron from a Tf complex. The complex can also contain, for instance, a carbonate, oxalate, or other anion to stabilize the Tf iron complex. | 11-24-2011 |
| 20110263489 | COMBINATION THERAPY TO COMBAT HELMINTH RESISTANCE - Pharmaceutical compositions having at least one crystal protein and a nicotinic acetylcholine receptor agonist in amounts effective to inhibit a parasitic worm or helminth infection in a vertebrate or mammal are described. Methods for treating a parasitic worm or helminth infection in a subject are also described. The methods include administering to the subject a therapeutically effective amount of the at least one crystal protein and a nicotinic acetylcholine receptor agonist. The crystal proteins can be isolated from | 10-27-2011 |
| 20110195907 | AMINO ACID AND PEPTIDE CONJUGATES OF AMILORIDE AND METHODS OF USE THEREOF - The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the treatment of a central nervous system disease or disorder or for the prevention or reduction of ischemia-reperfusion injury using the amiloride conjugates of the present invention. | 08-11-2011 |
| 20100184206 | TARGETING PSEUDOTYPED RETROVIRAL VECTORS - The present invention relates to retroviral vectors, particularly lentiviral vectors, pseudotyped with Sindbis envelope and targeted to specific cell types via a targeting moiety linked to the envelope. | 07-22-2010 |
| 20100173952 | METALLOPROTEIN INHIBITORS - The present invention relates to metalloprotein inhibitors comprising:
| 07-08-2010 |
| 20100119527 | N-CADHERIN: TARGET FOR CANCER DIAGNOSIS AND THERAPY - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers. | 05-13-2010 |
| 20100105105 | USE OF A REFERENCE SOURCE WITH ADAPTIVE OPTICS IN BIOLOGICAL MICROSCOPY - Methods of microscopic imaging of biological tissue using adaptive optics technology to improve the image focus and sharpness. Wavefront measurements are taken by using a novel method of seeding biological tissue by using a fluorescent microsphere as a “guide star” as a natural point-source reference. The current methods are capable of improving the Strehl ratio of modern biological microscopes as much as 15 times. | 04-29-2010 |
| 20090324551 | TLR AGONISTS - The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore. | 12-31-2009 |
| 20090137859 | PASSAGE EXPANSION DEVICE FOR PATIENTS - A method for opening a portion of a passageway of a patient is disclosed. The patient has a first metallic structure attached to a portion of the patient's neck. The method includes obtaining a second magnetic structure, placing the second magnetic structure proximate the first metallic structure attached to the portion of the patient's neck, and pulling the second magnetic structure away from the patient's neck to thereby open the passageway. | 05-28-2009 |
| 20090093003 | PORCINE UMAMI TASTE RECEPTORS AND USES THEREFOR - The present invention provides nucleic acids encoding porcine taste receptors, polypeptides encoded by the nucleic acids, and methods of using the nucleic acids and polypeptides to identify compounds that enhance umami taste. | 04-09-2009 |
| 20080306147 | Illudin Analogs Useful as Anticancer Agents - Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts, such as humans or animals, e.g., domestic animals, and are effective against solid tumors, hematologic malignancies and multi-drug resistant cancers/tumors. The present compounds can be used alone or they can be used in combination with one or more anti-cancer or anti-tumor agents. | 12-11-2008 |
